UBS Group
AGMB

UBS Group’s AgomAb Therapeutics NV AGMB Stock Holding History

UBS Group’s Portfolio AGMB Stock Details AGMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.6K Sell
2,128
-4,309
-67% -$48.5K ﹤0.01% 7949
2026
Q1 		$67.5K Buy
+6,437
New +$91.2K ﹤0.01% 7207

Other funds holding AGMB

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group's AGMB Position: Q2 2026 in Review

UBS Group reduced its AgomAb Therapeutics NV (AGMB) stake by 67% in Q2 2026, selling an estimated $48.5K and leaving 2,128 shares worth $27.6K. The position accounts for ﹤0.01% of the portfolio, ranked #7949.

UBS Group first reported a position in AGMB in Q1 2026 and has held it in 2 quarters since. The position peaked at $67.5K in Q1 2026. 34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

  • UBS Group held 2,128 shares of AgomAb Therapeutics NV worth $27.6K as of Q2 2026.
  • UBS Group sold 4,309 AgomAb Therapeutics NV shares in Q2 2026, an estimated $48.5K.
  • AgomAb Therapeutics NV made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7949 holding.
  • UBS Group first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 2 quarters since.
  • UBS Group's AgomAb Therapeutics NV position peaked at $67.5K in Q1 2026.
  • 34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.